We selected anakinra as our preferred IL‐1 blocker because, uniquely, it blocks both IL‐1α and IL‐1β, it has a rapid onset of action and established safety profile (> 70 000 patient‐years exposure), there was early evidence of benefit in pustular psoriasis and has the lowest drug acquisition costs. Here, IL1A is linked to pustular psoriasis.